Segall Bryant & Hamill LLC Sells 9,488 Shares of Vaxcyte, Inc. $PCVX

Segall Bryant & Hamill LLC cut its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 4.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 183,935 shares of the company’s stock after selling 9,488 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Vaxcyte were worth $10,688,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PCVX. Bank of America Corp DE raised its position in shares of Vaxcyte by 73.4% in the first quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock valued at $70,711,000 after purchasing an additional 515,209 shares during the period. Stempoint Capital LP bought a new position in Vaxcyte in the 1st quarter worth approximately $3,432,000. Janus Henderson Group PLC boosted its holdings in Vaxcyte by 23.8% in the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after buying an additional 3,188,687 shares during the period. Amundi grew its stake in Vaxcyte by 154.6% in the 1st quarter. Amundi now owns 12,958 shares of the company’s stock valued at $753,000 after buying an additional 7,868 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Vaxcyte by 68.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,248 shares of the company’s stock valued at $73,000 after buying an additional 507 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PCVX shares. Zacks Research downgraded Vaxcyte from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $86.00.

Vaxcyte Stock Performance

PCVX stock opened at $54.08 on Monday. The firm has a 50 day moving average of $53.25 and a 200-day moving average of $54.95. Vaxcyte, Inc. has a 12 month low of $29.08 and a 12 month high of $65.00. The firm has a market capitalization of $7.81 billion, a P/E ratio of -7.86 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period last year, the company earned ($1.04) EPS. Sell-side analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total value of $572,800.00. Following the sale, the chief financial officer owned 104,395 shares in the company, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer directly owned 158,494 shares of the company’s stock, valued at $7,848,622.88. This represents a 1.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 91,396 shares of company stock valued at $4,975,725 in the last three months. Company insiders own 3.30% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.